Results Healthcare advises GHO Capital on its acquisition of Sterling Pharma Solutions

  • Service: M&A
  • Sector: Healthcare
  • Sub Sector: CROs & CMOs
  • Engagement Type: Buy Side
Feb 2019
has acquired

We are delighted to announce that Results Healthcare acted as exclusive financial advisor to GHO Capital, on its acquisition, alongside management, of Sterling Pharma Solutions – a specialist in complex and difficult to manufacture APIs.

GHO Capital is a European specialist investor in healthcare and this transaction reinforces our expertise in driving value for private equity clients in the life sciences sector.

Headquartered in Newcastle upon Tyne, UK, Sterling is a leading provider of API development and manufacturing, with a reputation for world class quality standards.This is reflected in Sterling’s long-term relationships with blue-chip pharmaceutical and animal health clients, as well as a strong track record with global regulators including the FDA and EMA. Sterling delivers a full-service offering of API development and GMP manufacturing to support its customers throughout the entire product lifecycle.

Sterling is a provider of specialist services from clinical development through market launch to commercial supply. Outsourced small molecule API development and manufacturing is growing steadily at c. 7% per annum. This is overlaid with a long-term trend towards increasing molecule complexity, driving higher market growth rates in complex chemistry, where Sterling is an industry leader in Europe.

GHO Capital brings extensive sectoral expertise and networks in the global pharmaceutical and animal health industries, to support management in accelerating Sterling’s international growth.

Sector Related Deals

Jun 2022
A Kester Capital-backed company
has received investment from
Jun 2022
has been acquired by
A company backed by GTCR and The Carlyle Group
Mar 2022
has divested its Ringaskiddy, Ireland, manufacturing facility
Mar 2022
has divested its Boucherville, Canada manufacturing facility
Jan 2022
has divested its API manufacturing site in Cramlington, UK, to
Aug 2021
has been acquired by
an Odyssey Investment Partners-backed company
Jun 2021
has acquired a drug product manufacturing facility from
May 2021
has been acquired by
a Behrman Capital-backed company
Feb 2021
has been acquired by